within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05B_AntivaricoseTherapy.C05BB02_Polidocanol;

model Polidocanol
  extends Pharmacolibrary.Drugs.ATC.C.C05BB02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C05BB02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Polidocanol is a synthetic, non-ionic surfactant used medically as a sclerosing agent. It is primarily utilized in the treatment of varicose veins and spider veins through injection directly into the vessel. The drug works by damaging the endothelium of blood vessels, leading to thrombosis and eventual fibrosis. Polidocanol is approved for use in sclerotherapy in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are generally not well reported for polidocanol due to its local administration, and systemic absorption is considered minimal with clinical doses used for sclerotherapy in adult patients.</p><h4>References</h4><ol><li><p>Bai, T, et al., &amp; Fan, Y (2020). A Review of Sclerosing Foam Stability in the Treatment of Varicose Veins. <i>Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]</i> 46(2) 249–257. DOI:<a href=\"https://doi.org/10.1097/DSS.0000000000002039\">10.1097/DSS.0000000000002039</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31569112/\">https://pubmed.ncbi.nlm.nih.gov/31569112</a></p></li><li><p>Tröster, SD, &amp; Kreuter, J (1992). Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. <i>Journal of microencapsulation</i> 9(1) 19–28. DOI:<a href=\"https://doi.org/10.3109/02652049209021219\">10.3109/02652049209021219</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1613640/\">https://pubmed.ncbi.nlm.nih.gov/1613640</a></p></li><li><p>Machida, M, et al., &amp; Awazu, S (2000). The effects of absorption enhancers on the pulmonary absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. <i>Biological &amp; pharmaceutical bulletin</i> 23(1) 84–86. DOI:<a href=\"https://doi.org/10.1248/bpb.23.84\">10.1248/bpb.23.84</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10706417/\">https://pubmed.ncbi.nlm.nih.gov/10706417</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Polidocanol;
